The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue)
Part of paid clinical trials in Salt Lake City, Utah.
- Sponsor
- University of Utah
- Study ID
- NCT07151391
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Gynecologic Cancer
- Neuroendocrine Tumors
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Guarana — DRUG500 mg oral medication daily
- Placebo — DRUGOral medication daily
Study Details
The purpose of this clinical trial is to learn if the drug guarana improves symptoms of fatigue in patients with neuroendocrine tumors and gynecologic cancers
Key Dates
- Start date
- Sep 3, 2025
- Status verified
- Feb 2026
- Primary completion
- Sep 30, 2027
- Completion
- Sep 30, 2028
Study Design
- Enrollment
- 86 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: GuaranaThe study's goal is to determine the effect of Guarana on symptoms of fatigue
- Placebo Comparator: PlaceboThe study's goal is to determine the effect of Guarana on symptoms of fatigue
Primary Outcome Measure
Stage 1 Primary Change in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Fatigue 12 (EORTC QLQ-FA12) questionnaire scores from screening to Day 21 of guarana treatment. [ Time Frame: up to 21 days after initiation of study intervention ]
Central Contacts
- Susan Sharry801-585-3453
- Erin Ward, MD801-585-0236
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Huntsman Cancer Institute at University of Utah | Salt Lake City | Utah | 84112 |
Find similar trials in Salt Lake City, UT
By condition
By specialty
Related Studies
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA TherapyPHASE3 · Recruiting · RayzeBio, Inc. · Phoenix, Arizona
- Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor MalignanciesPHASE1 · Recruiting · Circle Pharma · Sarasota, Florida
- Transcranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy in Breast and Gynecologic Cancer SurvivorsRecruiting · University of Utah · Salt Lake City, Utah